Fatigue and associated factors in myasthenia gravis: a nationwide registry study.


Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
13 Jun 2024
Historique:
received: 19 03 2024
accepted: 29 05 2024
revised: 28 05 2024
medline: 14 6 2024
pubmed: 14 6 2024
entrez: 13 6 2024
Statut: aheadofprint

Résumé

Fatigue is commonly associated with myasthenia gravis (MG), but factors contributing to fatigue development in MG are incompletely understood. This nationwide cross-sectional registry study included 1464 patients diagnosed with autoimmune MG, recruited between February 2019 and April 2023. Frequency and severity of fatigue was assessed at study inclusion using the patient-reported Chalder Fatigue Questionnaire (CFQ). Frequency of fatigue was 59%. Fatigue severity strongly correlated with both patient-reported and physician-assessed MG outcome measures (MG-ADL, MG-QoL15, QMG and MGFA classes) and was associated with a history of myasthenic exacerbation and/or myasthenic crises and a delay in diagnosis of more than 1 year after symptom onset. Fatigue was more prevalent in women and coincided with symptoms of depression, anxiety, and sleep dissatisfaction. Differences in fatigue severity were observed between antibody (ab) subgroups, with highest fatigue severity in LRP4-ab-positive patients and lowest fatigue severity in AChR-ab-positive patients. Fatigue is a frequent and clinically highly relevant symptom of MG. Early diagnosis and prevention of MG crises may limit the long-term burden of fatigue in patients with MG.

Identifiants

pubmed: 38871821
doi: 10.1007/s00415-024-12490-2
pii: 10.1007/s00415-024-12490-2
doi:

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Gilhus NE, Tzartos S, Evoli A et al (2019) Myasthenia gravis. Nat Rev Dis Primers 5(1):30. https://doi.org/10.1038/s41572-019-0079-y
doi: 10.1038/s41572-019-0079-y pubmed: 31048702
Hoffmann S, Ramm J, Grittner U et al (2016) Fatigue in myasthenia gravis: risk factors and impact on quality of life. Brain and Behavior 6(10):e00538. https://doi.org/10.1002/brb3
doi: 10.1002/brb3 pubmed: 27781147 pmcid: 5064345
Alekseeva TM, Gavrilov YV, Kreis OA et al (2018) Fatigue in patients with myasthenia gravis. J Neurol 265(10):2312–2321. https://doi.org/10.1007/s00415-018-8995-4
doi: 10.1007/s00415-018-8995-4 pubmed: 30099585
Barnett C, Bril V, Kapral M et al (2014) A conceptual framework for evaluating impairments in myasthenia gravis. PLoS ONE 9(5):e98089. https://doi.org/10.1371/journal.pone.0098089
doi: 10.1371/journal.pone.0098089 pubmed: 24844418 pmcid: 4028305
Ruiter AM, Verschuuren JJGM, Tannemaat MR (2021) Prevalence and associated factors of fatigue in autoimmune myasthenia gravis. Neuromuscul Disord 31(7):612–621. https://doi.org/10.1016/j.nmd.2021.04.002
doi: 10.1016/j.nmd.2021.04.002 pubmed: 34034925
Melzer N, Ruck T, Fuhr P et al (2016) Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol 263(8):1473–1494. https://doi.org/10.1007/s00415-016-8045-z
doi: 10.1007/s00415-016-8045-z pubmed: 26886206 pmcid: 4971048
Chalder T, Berelowitz G, Pawlikowska T et al (1993) Development of a fatigue scale. J Psychosom Res 37(2):147–153. https://doi.org/10.1016/0022-3999(93)90081-p
doi: 10.1016/0022-3999(93)90081-p pubmed: 8463991
Paul RH, Cohen RA, Goldstein JM et al (2000) Fatigue and its impact on patients with myasthenia gravis. Muscle Nerve 23(9):1402–1406. https://doi.org/10.1002/1097-4598(200009)23:9%3c1402:aid-mus11%3e3.0.co;2-b
doi: 10.1002/1097-4598(200009)23:9<1402:aid-mus11>3.0.co;2-b pubmed: 10951443
Elsais A, Wyller VB, Loge JH et al (2013) Fatigue in myasthenia gravis: is it more than muscular weakness? BMC Neurol 13:132. https://doi.org/10.1186/1471-2377-13-132
doi: 10.1186/1471-2377-13-132 pubmed: 24088269 pmcid: 3852076
Kittiwatanapaisan W, Gauthier DK, Williams AM et al (2003) Fatigue in myasthenia gravis patients. J Neurosci Nurs 35(2):87–106. https://doi.org/10.1097/01376517-200304000-00004
doi: 10.1097/01376517-200304000-00004 pubmed: 12795035
Lehnerer S, Jacobi J, Schilling R et al (2022) Burden of disease in myasthenia gravis: taking the patient’s perspective. J Neurol 269(6):3050–3063. https://doi.org/10.1007/s00415-021-10891-1
doi: 10.1007/s00415-021-10891-1 pubmed: 34800167
Dewilde S, Phillips G, Paci S et al (2023) The burden patients with myasthenia gravis experience in terms of breathing, fatigue, sleep, mental health, discomfort and usual activities in comparison to the general population. Adv Ther 41(1):271–291. https://doi.org/10.1007/s12325-023-02704-w
doi: 10.1007/s12325-023-02704-w pubmed: 37921955 pmcid: 10796601
Marbin D, Piper SK, Lehnerer S et al (2022) Mental health in myasthenia gravis patients and its impact on caregiver burden. Sci Rep 12(1):19275. https://doi.org/10.1038/s41598-022-22078-3
doi: 10.1038/s41598-022-22078-3 pubmed: 36369246 pmcid: 9652470
Zielinski MR, Systrom DM, Rose NR (2019) Fatigue, Sleep, and autoimmune and related disorders. Front Immunol 10:1827. https://doi.org/10.3389/fimmu.2019.01827
doi: 10.3389/fimmu.2019.01827 pubmed: 31447842 pmcid: 6691096
Liu C, Li T, Wang Q et al (2021) Post-traumatic stress disorder symptoms after respiratory insufficiency in patients with myasthenia gravis. Psychol Health Med 26(2):221–227. https://doi.org/10.1080/13548506.2020.1807577
doi: 10.1080/13548506.2020.1807577 pubmed: 32877257
Sobierajski T, Lasek-Bal A, Krzystanek M et al (2023) Diagnosis and therapy of myasthenia gravis-the patients’ perspective: a cross-sectional study. Front Neurol 14:1214041. https://doi.org/10.3389/fneur.2023.1214041
doi: 10.3389/fneur.2023.1214041 pubmed: 37602258 pmcid: 10437051

Auteurs

Mattea Funke (M)

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, 48149, Münster, Germany.

Maria Eveslage (M)

Institute of Biostatistics and Clinical Research, University of Münster, 48149, Münster, Germany.

Jana Zschüntzsch (J)

Department of Neurology, University Medical Center Göttingen, Georg-August University, 37075, Göttingen, Germany.

Tim Hagenacker (T)

Department of Neurology, Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.

Tobias Ruck (T)

Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

Charlotte Schubert (C)

Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Michael Schroeter (M)

Department of Neurology, University Cologne and University Hospital, Cologne, Germany.

Andreas Meisel (A)

Charité - Universitätsmedizin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Center for Stroke Research Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.

Heinz Wiendl (H)

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, 48149, Münster, Germany.

Sarah Hoffmann (S)

Charité - Universitätsmedizin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Center for Stroke Research Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.

Jan D Lünemann (JD)

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, 48149, Münster, Germany. jan.luenemann@ukmuenster.de.

Classifications MeSH